The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Practical advice for the management of patients with CML who are pregnant or wish to conceive
Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, summarizes her talk on fertility and pregnancy in patients with chronic myeloid leukemia (CML). Current data suggest that cessation of therapy is not necessary for male patients who wish to conceive with their female partners. However, as tyrosine kinase inhibitor (TKI) therapy is teratogenic and embryotoxic, great care must be taken to stop TKIs in female patients during the period of organogenesis. Imatinib and nilotinib can be used once placental formation has occurred, and interferon appears to be safe to use throughout the pregnancy. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
